<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307201</url>
  </required_header>
  <id_info>
    <org_study_id>complejoh</org_study_id>
    <nct_id>NCT02307201</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia</brief_title>
  <acronym>MAG-PIP</acronym>
  <official_title>Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complejo Hospitalario Dr. Arnulfo Arias Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complejo Hospitalario Dr. Arnulfo Arias Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no evidence that patients receiving magnesium sulfate before birth are required to&#xD;
      maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical&#xD;
      study in patients with severe preeclampsia who have been treated with impregnation of&#xD;
      magnesium sulphate and at least eight hours have received the drug before birth. If the&#xD;
      patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours&#xD;
      postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other&#xD;
      anticonvulsant drugs. This study can be conducted in 12 maternity latin america.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The final treatment known for pre-eclampsia and eclampsia is the termination of pregnancy.&#xD;
      However to prevent eclampsia in patients with severe pre-eclampsia has been demonstrated the&#xD;
      effectiveness of magnesium sulfate. There are multiple studies that prove the effectiveness&#xD;
      of magnesium sulfate to prevent eclampsia in patients with severe disorder of blood pressure&#xD;
      during pregnancy. These studies used the drug before birth and continue after birth.&#xD;
      Therefore the investigators can not conclude whether the administration just before pregnancy&#xD;
      is sufficient to prevent seizure. If the cure or definitive treatment of pre-eclampsia is the&#xD;
      interruption, did not seem necessary to justify the administration of drugs anti-eclampsia&#xD;
      after birth. Obvious post delivery management with magnesium sulfate arises from the large&#xD;
      number of postpartum eclampsia reported in many studies. It is unknown whether administration&#xD;
      of magnesium sulfate for a minimum period before delivery, requires even keep the drug post&#xD;
      partum.&#xD;
&#xD;
      In addition to magnesium sulfate postpartum, is necessary to maintain urinary catheter to&#xD;
      monitoring the removal of magnesium sulfate; is usual to maintain the patient at all or&#xD;
      almost all rest by monitoring sulfate and diuresis , this prevents a proper relationship&#xD;
      mother and babe and even prevents breastfeeding during that period and is also known&#xD;
      increased risk of secondary thromboembolism due to prolonged rest in the postpartum /&#xD;
      caesarean section.Thus, maintain magnesium sulfate for 24 hours carries a higher cost,&#xD;
      greater vigilance and some risks, without known real effect.&#xD;
&#xD;
      A randomized clinical study conducted by Belfort and colleagues and published in January&#xD;
      2003, where magnesium sulphate compared to nimodipine to prevent eclampsia in women with&#xD;
      severe pre-eclampsia, showed interesting outcome. Such research analyzed 819 randomized&#xD;
      patients in the nimodipine group and 831 in the magnesium sulfate group. Magnesium sulphate&#xD;
      was better than Nimodipine in preventing eclampsia. Interestingly, the greater effectiveness&#xD;
      of sulfate appears to prevent all eclampsia postpartum (9 vs 0) and obviously was used before&#xD;
      the termination of pregnancy, however no difference compared with nimodipine in eclampsia&#xD;
      before birth (12 vs 7).&#xD;
&#xD;
      There are two possible reasons for the non-appearance of postpartum eclampsia: 1- maintain&#xD;
      postpartum magnesium sulfate, 2- dose 12-13 grams before birth disruption are sufficient to&#xD;
      prevent eclampsia.&#xD;
&#xD;
      The MAGPIE study randomized 1335 postpartum patients (unused sulphate before delivery) using&#xD;
      magnesium sulfate postpartum / cesarean (696 women) or placebo postpartum / cesarean (639&#xD;
      women), and found no significant difference in the amount of eclampsia . Thus, the use of&#xD;
      magnesium sulfate for first time in the postpartum is not better to use a placebo. If the&#xD;
      investigators combine the findings of eclampsia postpartum Belfort study and MAGPIE study is&#xD;
      logical to think that the success of the Belfort study in the postpartum is not for the use&#xD;
      of magnesium sulfate post delivery and not only due to the termination of pregnancy because&#xD;
      there are postpartum eclampsia in the nimodipine group.&#xD;
&#xD;
      If the investigators consider unjustified use of magnesium sulfate postpartum, when&#xD;
      maintained at least 8 hours before delivery, the investigators decided to make a&#xD;
      non-inferiority randomized study.The investigators assume that using or not using magnesium&#xD;
      sulfate during the postpartum prevents similar amount of postpartum eclampsia, if during&#xD;
      pregnancy was used (impregnation and at least 8 hours before birth).&#xD;
&#xD;
      For all these reasons the investigators propose the following: A randomized trial is&#xD;
      necessary where all those patients who received magnesium sulfate for at least 8 hours before&#xD;
      birth (involves impregnation and maintenance 8 hours) will be randomized to two groups of&#xD;
      study: 1- Continue magnesium sulfate for 24 hours and 2-not use magnesium sulfate or other&#xD;
      anticonvulsant drug post delivery.&#xD;
&#xD;
      This study is planned in 12 maternity latin america&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eclampsia</measure>
    <time_frame>24 hours postpartum</time_frame>
    <description>Convulsion after delivery in any group (with magnesium sulfate or without magnesium sulfate), during 24 hours postpartum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>24 hours postpartum</time_frame>
    <description>Blood loss &gt; 500 post vaginal delivery or &gt; 800 cc post cesarean section, during 24 hours postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal respiratory distress</measure>
    <time_frame>24 hours postpartum</time_frame>
    <description>clinical respiratory distress,during 24 hours postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grams of magnesium sulfate before delivery</measure>
    <time_frame>8 to 72 hours with magnesium sulfate before delivery</time_frame>
    <description>Hours and grams of magnesium sulfate before delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypertension postpartum</measure>
    <time_frame>72 hours postdelivery</time_frame>
    <description>Diastolic Blood pressure &gt; 110 mmHg and/or systolic blood pressure &gt; 160 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1114</enrollment>
  <condition>Post Partum Severe Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Postpartum Magnesium sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive magnesium sulfate as usual for 24 hours postpartum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No postpartum treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>The patient will receive magnesium sulfate for 24 hours postpartum</description>
    <arm_group_label>Postpartum Magnesium sulfate</arm_group_label>
    <other_name>No postpartum treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe preeclampsia or severe preeclampsia aggregated to chronic hypertension with &gt;&#xD;
             24 weeks of gestation treated with 4-6 grams of magnesium sulfate for impregnation&#xD;
             with a minimum of 8 hours continuous of magnesium sulfate before delivery&#xD;
&#xD;
          -  The study begins to terminate pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HELLP syndrome&#xD;
&#xD;
          -  Eclampsia&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Disease of collagen&#xD;
&#xD;
          -  Heart disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulino Vigil De Gracia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Dr. Arnulfo Arias Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Ludmir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>School of medicine, Pennsylvania Hospital. University de Pennsylvania. Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Materno Infantil san Lorezo de las Minas</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Maternidad Nuestra señoa de Alta Gracia</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Teodoro Maldonado De Guayaquil</name>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Primero de Mayo</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jose Domingo De Obaldia</name>
      <address>
        <city>Chiriqui</city>
        <zip>507</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Caja de Seguro Social</name>
      <address>
        <city>Panamá</city>
        <zip>507</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santo Tomás</name>
      <address>
        <city>Panamá</city>
        <zip>507</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Cojamarca, Perú,</name>
      <address>
        <city>Cajamarca</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Materno perinatal, Maternidad de Lima</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Ecuador</country>
    <country>El Salvador</country>
    <country>Panama</country>
    <country>Peru</country>
  </location_countries>
  <removed_countries>
    <country>Guatemala</country>
    <country>Honduras</country>
    <country>Mexico</country>
    <country>Paraguay</country>
    <country>Uruguay</country>
  </removed_countries>
  <reference>
    <citation>Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11.</citation>
    <PMID>12540643</PMID>
  </reference>
  <results_reference>
    <citation>Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90.</citation>
    <PMID>12057549</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Dr. Arnulfo Arias Madrid</investigator_affiliation>
    <investigator_full_name>Paulino Vigil-De Gracia</investigator_full_name>
    <investigator_title>MEDICAL DOCTOR, GYNECOLOGY AND OBSTETRIC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

